Regeneron Antibody Treatment Helps Restore Muscle Loss in GLP-1 Therapy Discontinuation
Regeneron presented mid-stage trial data showing its investigational antibody could help obese patients recover muscle mass they lost while taking Novo's Wegovy GLP-1 medication. The therapy demonstrated the ability to restore muscle comparable to the amount that was depleted during GLP-1 treatment. The findings address a known side effect concern with weight-loss medications that can result in muscle loss alongside fat reduction.
Regeneron's investigational antibody treatment has shown promise in addressing a significant drawback associated with popular weight-loss drugs like Novo Nordisk's Wegovy. When patients discontinue GLP-1 medications, this experimental therapy may help them regain muscle tissue that had been lost during treatment. The mid-stage trial results indicate the antibody could restore muscular strength at levels comparable to the depletion experienced while on the weight-loss regimen.
This development responds to growing concerns within the medical community about GLP-1 drugs' tendency to reduce muscle alongside fat during weight loss. Preserving or recovering muscle mass is important for overall health and metabolic function, making adjunctive treatments that address this side effect potentially valuable for patients undergoing obesity treatment.
If successful in later trials, this approach could benefit millions of patients using GLP-1 medications by mitigating a significant health concern associated with their use. The treatment may widen access to weight-loss therapy by reducing hesitation among patients worried about muscle loss. Healthcare providers might offer combination strategies to optimize outcomes, though widespread adoption would depend on efficacy confirmation, regulatory approval, and cost considerations.